Bruker Corporation Completes Acquisition of PhenomeX, Expanding its Single-Cell Biology Research Tools

Bruker Corporation, a leading provider of high-performance scientific instruments and analytical solutions, has successfully finalized its acquisition of PhenomeX, a prominent company specializing in single-cell biology research tools. The acquisition was completed for a cash consideration of $108 million.

PhenomeX is recognized for its innovative platforms, including the Beacon® line of Optofluidic systems, which enable researchers to gain deep insights into cellular function and establish connections between phenotype and genotype. These tools are highly valued in various growth markets such as antibody development, cell line development, and cell and gene therapy.

Dr. Mark R. Munch, President of the Bruker NANO Group, expressed excitement about the addition of PhenomeX to Bruker’s portfolio. He highlighted the complementarity of PhenomeX’s platforms with Bruker’s existing cellular and sub-cellular analysis tools, including the high-performance CellScape™ spatial biology platform.

Bruker plans to optimize PhenomeX’s cost structure immediately. While the acquisition is expected to be slightly dilutive to Bruker’s non-GAAP EPS in 2024 and 2025, it is projected to become accretive to non-GAAP EPS starting in 2026. More details regarding the financial impact of PhenomeX will be provided during Bruker’s Q3 2023 earnings release.

Following the transaction’s completion, PhenomeX’s common stock will no longer be listed for trading on the Nasdaq Global Market. Additionally, PhenomeX will undergo a name change in the near future.

Bruker Corporation, known for enabling breakthrough discoveries and applications that enhance human life, offers a wide range of high-performance scientific instruments and diagnostic solutions. The company collaborates closely with customers to drive innovation and success in various fields, including life science research, applied and pharma applications, microscopy and nanoanalysis, and industrial applications.

For more information about Bruker Corporation, please visit: www.bruker.com.

Cautionary Statement Regarding Forward-Looking Statements:
This communication contains forward-looking statements related to Bruker’s acquisition of PhenomeX. Readers are advised that these statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those anticipated due to various factors. For a detailed discussion of the risks and uncertainties, please refer to Bruker’s most recent Form 10-K and Form 10-Q filings with the SEC. Bruker does not undertake any obligation to update forward-looking statements.

Source: [Business Wire](https://www.businesswire.com/news/home/20231003528133/en/)